Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Fintel reports that on July 22, 2025, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 725.97% Upside As of July 17, ...

Replimune Group (NASDAQ:REPL – Get Free Report) ‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports ...